Cipla today announced that it has received final approval for its Abbreviated New Drug Application (ANDA) for Medroxyprogesterone Injectable, 150mg/mL from the United States Food and Drug Administration (US FDA).

Cipla's Medroxyprogesterone Injectable, 150mg/mL is AB-rated generic therapeutic equivalent version of Pfizer's Depo-Provera. It is a progestin indicated only for the prevention of pregnancy. According to IQVIA (IMS Health), Depo-Provera and its generic equivalents had US sales of approximately USD 159M for the 12-month period ending November 2018.

Shares of the company gained Rs 3.1, or 0.61%, to trade at Rs 510.00. The total volume of shares traded was 0 at the BSE (9.02 a.m., Monday).